Achaogen (AKAOQ) Stock Price
Achaogen Price
Revenue at Achaogen has contracted by 12.6% per year over the past 7 years to 8.73 M USD. For Achaogen, the net margin of -2,136.9% is down versus -101.0% a few years ago.
Achaogen stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Achaogen over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Achaogen stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Achaogen's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Achaogen Price |
|---|
Achaogen Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Achaogen Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019e | 2020e |
|---|---|---|---|---|---|---|---|---|---|
| 22.00 | 17.00 | 18.00 | 19.00 | 26.00 | 41.00 | 11.00 | 8.00 | 13.00 | 18.00 |
| – | -22.73 | 5.88 | 5.56 | 36.84 | 57.69 | -73.17 | -27.27 | 62.50 | 38.46 |
| 36.36 | 47.06 | 44.44 | 42.11 | -53.85 | -78.05 | -763.64 | 100.00 | 100.00 | 100.00 |
| 8.00 | 8.00 | 8.00 | 8.00 | -14.00 | -32.00 | -84.00 | 8.00 | 13.00 | 18.00 |
| -20.00 | -15.00 | -11.00 | -19.00 | -26.00 | -49.00 | -126.00 | -181.00 | – | – |
| -90.91 | -88.24 | -61.11 | -100.00 | -100.00 | -119.51 | -1,145.45 | -2,262.50 | – | – |
| -20.00 | -18.00 | -13.00 | -20.00 | -27.00 | -71.00 | -125.00 | -186.00 | – | – |
| – | -10.00 | -27.78 | 53.85 | 35.00 | 162.96 | 76.06 | 48.80 | – | – |
| 15.78 | 15.78 | 15.78 | 14.21 | 14.21 | 14.21 | 14.21 | 14.21 | 14.21 | 14.21 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Achaogen generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Achaogen retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Achaogen's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Achaogen has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Achaogen's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Achaogen stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Achaogen Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Achaogen business model & stock analysis
Achaogen SWOT Analysis
Strengths
1. Strong portfolio of innovative antibiotic drugs.
2. Patented technology and intellectual property rights.
3. Skilled and experienced research and development team.
4. Strong financial performance and revenue growth.
Weaknesses
1. Relatively small market share compared to larger pharmaceutical companies.
2. Dependence on a limited number of key drugs for revenue generation.
3. Costly and time-consuming regulatory approval process.
4. Vulnerability to patent expirations and generic competition.
Opportunities
1. Increasing global prevalence of antibiotic-resistant infections.
2. Growing demand for effective antibiotics in emerging markets.
3. Collaboration opportunities with other pharmaceutical companies.
4. Potential for expansion into related therapeutic areas.
Threats
1. Intense competition within the antibiotics market.
2. Regulatory uncertainties and changing government policies.
3. Potential negative public perception of antibiotics and their overuse.
4. Risk of emerging superbugs with resistance to existing antibiotics.
Achaogen Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Achaogen historical P/E ratio, EBIT multiple, and P/S ratio
Achaogen annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Achaogen shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Frequently asked questions about Achaogen
The business model of Achaogen Inc revolves around developing and commercializing innovative antibacterial therapies for serious infections caused by multidrug-resistant bacteria. Achaogen Inc focuses on discovering and developing drugs that target bacterial pathogens resistant to existing antibiotics. The company aims to address the urgent need for new antibiotics through its research and development efforts. By leveraging its expertise in antibiotic drug discovery and development, Achaogen Inc strives to provide new treatment options for patients and healthcare providers combating drug-resistant infections.
Achaogen Inc is primarily active in the pharmaceutical industry.
The main competitors of Achaogen Inc in the market are pharmaceutical companies focused on the development and commercialization of antibiotics and antimicrobial agents. Some notable competitors include Merck & Co., Pfizer Inc., GlaxoSmithKline, Novartis AG, and Roche Holding AG. These companies, like Achaogen Inc, are actively engaged in the research, development, and commercialization of innovative therapies to combat antibiotic-resistant infections. They compete for market share and strive to address unmet medical needs in the field of infectious diseases.
Achaogen Inc is a biopharmaceutical company based in South San Francisco, California. Founded in 2002, the company specializes in the discovery, development, and commercialization of innovative antibacterial treatments. Achaogen Inc is dedicated to addressing the growing threat of antibiotic resistance by utilizing its expertise in research and development. With a focus on serious infections caused by multidrug-resistant bacteria, the company aims to provide patients with groundbreaking therapeutic options. Over the years, Achaogen Inc has made significant advancements in the field of antibacterial treatments, cementing its position as a leader in the industry.
Achaogen Inc. has achieved several significant milestones in its history. The company successfully developed ZEMDRI® (plazomicin), an antibiotic used for the treatment of adults with complicated urinary tract infections (cUTI) including pyelonephritis. In addition, Achaogen Inc. secured FDA approval for ZEMDRI® in June 2018, becoming the company's first commercialized product. The accomplishment showcased the company's capabilities in developing innovative therapies to combat serious infections. Achaogen Inc. also secured multiple grants and collaborations, including support from the Biomedical Advanced Research and Development Authority (BARDA) and partnerships with other healthcare organizations. These achievements reflect the company's commitment to addressing critical medical needs and advancing the field of antibiotic research and development.
Achaogen Inc is primarily present in the United States, focusing on the development and commercialization of innovative antibacterial treatments.
Achaogen Inc represents values of innovation, dedication, and patient-centeredness. As a leading biopharmaceutical company, Achaogen Inc is committed to developing and commercializing innovative antibacterial treatments to address the urgent global health threats posed by multi-drug resistant infections. With a corporate philosophy centered around advancing the standard of care for patients, Achaogen Inc strives to provide effective and safe antibiotics that target bacteria resistant to traditional treatment options. By leveraging cutting-edge research and development technologies, Achaogen Inc aims to make a positive impact on public health by addressing the unmet medical needs of patients suffering from serious infections.
Achaogen Inc. is a biopharmaceutical company focused on the development and commercialization of innovative antibiotics for the treatment of severe bacterial infections. The company was founded in 2002 and is headquartered in South San Francisco, California. Achaogen has a diverse portfolio of products, including Zemdri, the only approved intravenous antibiotic for the treatment of patients with complicated urinary tract infections (cUTI) when other antibiotics do not work. It is also a significant partner in public health and offers specialized consulting services for clinical microbiology and infection control. Achaogen's business model is focused on the discovery and development of antibiotics against antibiotic resistance and serious infectious diseases. The company aims to bring new antibiotics to market to meet the growing need for effective antibiotics that are effective against bacterial infections that have become resistant to conventional antibiotics. Achaogen uses a unique business model that focuses on three main areas: the discovery and development of novel antibiotics for MDR infections, the clinical development of antibiotics, and innovative services for microbiologists and infection control professionals. Overall, Achaogen's business model has proven successful, particularly in the face of advancing antibiotic resistance. The company understands the importance of continued research and development of antibiotics and is committed to providing new and innovative solutions for severe bacterial infections. Through its unique research and development strategy, clinical development, and comprehensive services, Achaogen Inc. has a strong position in the field of antibiotic research and development.
The revenue cannot currently be calculated for Achaogen.
The profit cannot currently be calculated for Achaogen.
The P/E ratio cannot be calculated for Achaogen at the moment.
The P/S cannot be calculated for Achaogen currently.
The Eulerpool Quality Score for Achaogen is 2/10.
The ISIN of Achaogen is US0044491043. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Achaogen is A1XFMJ. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Achaogen is AKAOQ. The ticker symbol is used to trade Achaogen shares on the stock exchange.
Achaogen is assigned to the 'Health' sector.
The dividends of Achaogen are distributed in USD.
Achaogen stock
Achaogen Peer Group
Achaogen FIGI
All fundamentals and in-depth analysis of Achaogen
Our stock analysis for Achaogen stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Achaogen. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.